AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
gadopiclenol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| diagnostic agents, gadolinium derivatives | 5681 | 933983-75-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Gadopiclenol is a paramagnetic molecule (macrocyclic non-ionic complex of gadolinium) that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 | 35 | |||
| kinase-selectivity-class | ACVRL1,AXL,BRAF,CDK4,CDK9,CHUK,EPHB4,GRK2,MAP2K6,PIK3CB,PIK3CD,TEK,TGFBR1 | 13 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 21, 2022 | FDA | GUERBET S.A. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V08CA12 | VARIOUS CONTRAST MEDIA MAGNETIC RESONANCE IMAGING CONTRAST MEDIA Paramagnetic contrast media |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
Related Drugs by ATC class:
V08CA Paramagnetic contrast media 10 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Detect and visualize lesions with abnormal vascularity with MRI | indication | 767426001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.4553GM/3ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | 12064487 | Jan. 17, 2040 | METHOD OF MAGNETIC RESONANCE IMAGING TO DETECT AND VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE CENTRAL NERVOUS SYSTEM (BRAIN, SPINE, AND ASSOCIATED TISSUES) AND THE BODY (HEAD AND NECK, THORAX, ABDOMEN, PELVIS, AND MUSCULOSKELETAL SYSTEM) |
| 14.553GM/30ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | 12064487 | Jan. 17, 2040 | METHOD OF MAGNETIC RESONANCE IMAGING TO DETECT AND VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE CENTRAL NERVOUS SYSTEM (BRAIN, SPINE, AND ASSOCIATED TISSUES) AND THE BODY (HEAD AND NECK, THORAX, ABDOMEN, PELVIS, AND MUSCULOSKELETAL SYSTEM) |
| 24.255GM/50ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | 12064487 | Jan. 17, 2040 | METHOD OF MAGNETIC RESONANCE IMAGING TO DETECT AND VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE CENTRAL NERVOUS SYSTEM (BRAIN, SPINE, AND ASSOCIATED TISSUES) AND THE BODY (HEAD AND NECK, THORAX, ABDOMEN, PELVIS, AND MUSCULOSKELETAL SYSTEM) |
| 3.63825GM/7.5ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | 12064487 | Jan. 17, 2040 | METHOD OF MAGNETIC RESONANCE IMAGING TO DETECT AND VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE CENTRAL NERVOUS SYSTEM (BRAIN, SPINE, AND ASSOCIATED TISSUES) AND THE BODY (HEAD AND NECK, THORAX, ABDOMEN, PELVIS, AND MUSCULOSKELETAL SYSTEM) |
| 4.851GM/10ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | 12064487 | Jan. 17, 2040 | METHOD OF MAGNETIC RESONANCE IMAGING TO DETECT AND VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE CENTRAL NERVOUS SYSTEM (BRAIN, SPINE, AND ASSOCIATED TISSUES) AND THE BODY (HEAD AND NECK, THORAX, ABDOMEN, PELVIS, AND MUSCULOSKELETAL SYSTEM) |
| 7.2765GM/15ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | 12064487 | Jan. 17, 2040 | METHOD OF MAGNETIC RESONANCE IMAGING TO DETECT AND VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE CENTRAL NERVOUS SYSTEM (BRAIN, SPINE, AND ASSOCIATED TISSUES) AND THE BODY (HEAD AND NECK, THORAX, ABDOMEN, PELVIS, AND MUSCULOSKELETAL SYSTEM) |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 1.4553GM/3ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | Sept. 21, 2027 | NEW CHEMICAL ENTITY |
| 14.553GM/30ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | Sept. 21, 2027 | NEW CHEMICAL ENTITY |
| 24.255GM/50ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | Sept. 21, 2027 | NEW CHEMICAL ENTITY |
| 3.63825GM/7.5ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | Sept. 21, 2027 | NEW CHEMICAL ENTITY |
| 4.851GM/10ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | Sept. 21, 2027 | NEW CHEMICAL ENTITY |
| 48.51GM/100ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | Sept. 21, 2027 | NEW CHEMICAL ENTITY |
| 7.2765GM/15ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | Sept. 21, 2027 | NEW CHEMICAL ENTITY |
| 1.4553GM/3ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | Feb. 20, 2029 | NEW PATIENT POPULATION |
| 14.553GM/30ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | Feb. 20, 2029 | NEW PATIENT POPULATION |
| 24.255GM/50ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | Feb. 20, 2029 | NEW PATIENT POPULATION |
| 3.63825GM/7.5ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | Feb. 20, 2029 | NEW PATIENT POPULATION |
| 4.851GM/10ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | Feb. 20, 2029 | NEW PATIENT POPULATION |
| 48.51GM/100ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | Feb. 20, 2029 | NEW PATIENT POPULATION |
| 7.2765GM/15ML (485.1MG/ML) | ELUCIREM | GUERBET | N216986 | Sept. 21, 2022 | RX | SOLUTION | INTRAVENOUS | Feb. 20, 2029 | NEW PATIENT POPULATION |
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| CHEBI:757103 | CHEBI |
| CHEMBL4297634 | ChEMBL_ID |
| C000656634 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB17084 | DRUGBANK_ID |
| 4041872 | VANDF |
| C5392287 | UMLSCUI |
| 10744 | INN_ID |
| D12435 | KEGG_DRUG |
| 16223405 | PUBCHEM_CID |
| 368327 | MMSL |
| 41266 | MMSL |
| d10016 | MMSL |
| 019209 | NDDF |
| S276568KOY | UNII |
| 2618720 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Vueway | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0270-7015 | INJECTION | 485.10 mg | INTRAVENOUS | NDA | 27 sections |
| Vueway | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0270-7020 | INJECTION | 485.10 mg | INTRAVENOUS | NDA | 27 sections |
| Vueway | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0270-7025 | INJECTION | 485.10 mg | INTRAVENOUS | NDA | 27 sections |
| Vueway | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0270-7030 | INJECTION | 485.10 mg | INTRAVENOUS | NDA | 27 sections |
| Vueway | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0270-7035 | INJECTION | 485.10 mg | INTRAVENOUS | NDA | 27 sections |
| ELUCIREM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67684-4230 | INJECTION | 485.10 mg | INTRAVENOUS | NDA | 29 sections |
| ELUCIREM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67684-4231 | INJECTION | 485.10 mg | INTRAVENOUS | NDA | 29 sections |
| ELUCIREM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67684-4232 | INJECTION | 485.10 mg | INTRAVENOUS | NDA | 29 sections |
| ELUCIREM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67684-4233 | INJECTION | 485.10 mg | INTRAVENOUS | NDA | 29 sections |
| ELUCIREM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67684-4240 | INJECTION | 485.10 mg | INTRAVENOUS | NDA | 29 sections |
| ELUCIREM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67684-4241 | INJECTION | 485.10 mg | INTRAVENOUS | NDA | 29 sections |
| ELUCIREM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67684-4242 | INJECTION | 485.10 mg | INTRAVENOUS | NDA | 29 sections |
| ELUCIREM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67684-4250 | INJECTION | 485.10 mg | INTRAVENOUS | NDA | 29 sections |
| ELUCIREM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67684-4251 | INJECTION | 485.10 mg | INTRAVENOUS | NDA | 29 sections |